New drug vixarelimab tested for Tough-to-Treat ulcerative colitis
NCT ID NCT06693908
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 4 times
Summary
This early-stage trial is testing a drug called vixarelimab in 24 people with moderate to severe ulcerative colitis who have not improved with standard treatments. The study looks at how the drug affects the gut, how it moves through the body, and whether it is safe. It is too early to know if it will help symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vixarelimab
- What this could lead to
- If successful, this could point toward a new treatment option for people with moderate to severe ulcerative colitis who have not responded to other therapies.
- What could go wrong
- This is a very early, small study (24 people) focused on safety and biological effects, not yet on symptom improvement. The drug may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Charité Research Organisation GmbH
Berlin, 10117, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill tame ulcerative colitis?
- Could a new injection tame ulcerative colitis?
- New study explores simple tests to replace colonoscopies for colitis patients
- New pill could tame severe gut disease
- New drug shows promise for ulcerative colitis sufferers
- Immune cell therapy takes on IBD: a new hope for tough cases?